BR112014000965B8 - Método, aparelho e meio de armazenamento não transitório - Google Patents
Método, aparelho e meio de armazenamento não transitórioInfo
- Publication number
- BR112014000965B8 BR112014000965B8 BR112014000965A BR112014000965A BR112014000965B8 BR 112014000965 B8 BR112014000965 B8 BR 112014000965B8 BR 112014000965 A BR112014000965 A BR 112014000965A BR 112014000965 A BR112014000965 A BR 112014000965A BR 112014000965 B8 BR112014000965 B8 BR 112014000965B8
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- trainer
- appliance
- tissue
- storage media
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N5/00—Computing arrangements using knowledge-based models
- G06N5/04—Inference or reasoning models
- G06N5/048—Fuzzy inferencing
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/30—Detection of binding sites or motifs
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
- G16B5/20—Probabilistic models
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Molecular Biology (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Data Mining & Analysis (AREA)
- Immunology (AREA)
- Software Systems (AREA)
- General Engineering & Computer Science (AREA)
- Evolutionary Computation (AREA)
- Artificial Intelligence (AREA)
- Physiology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Databases & Information Systems (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Bioethics (AREA)
- Pathology (AREA)
- Probability & Statistics with Applications (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Mathematical Physics (AREA)
Abstract
MÉTODO, E APARELHO. O presente pedido de patente principalmente refere-se a métodos específicos para inferir a atividade de uma ou mais via(s) de sinalização celular no tecido de um indivíduo sob avaliação médica, pelo menos com base no(s) nível(is) de expressão de um ou mais gene(s)-alvo da(s) via(s) de sinalização celular medido(s) em uma amostra extraída do tecido do material médico, um aparelho compreendendo um compressor digital configurado para realizar tais métodos e um meio de armazenamento não-transitório armazenando instruções que são executáveis por um dispositivo de processamento digital para realizar tais métodos.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161509137P | 2011-07-19 | 2011-07-19 | |
US61/509,137 | 2011-07-19 | ||
EP11178148.0 | 2011-08-19 | ||
EP11178148A EP2549399A1 (en) | 2011-07-19 | 2011-08-19 | Assessment of Wnt pathway activity using probabilistic modeling of target gene expression |
PCT/IB2012/053686 WO2013011479A2 (en) | 2011-07-19 | 2012-07-19 | Assessment of cellular signaling pathway activity using probabilistic modeling of target gene expression |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112014000965A2 BR112014000965A2 (pt) | 2017-06-13 |
BR112014000965B1 BR112014000965B1 (pt) | 2021-08-24 |
BR112014000965B8 true BR112014000965B8 (pt) | 2022-11-08 |
Family
ID=44582424
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014000965A BR112014000965B8 (pt) | 2011-07-19 | 2012-07-19 | Método, aparelho e meio de armazenamento não transitório |
Country Status (12)
Country | Link |
---|---|
US (2) | US11443831B2 (pt) |
EP (6) | EP2549399A1 (pt) |
JP (3) | JP6204354B2 (pt) |
KR (1) | KR102064004B1 (pt) |
CN (2) | CN109852671A (pt) |
BR (1) | BR112014000965B8 (pt) |
DK (3) | DK2734643T3 (pt) |
ES (3) | ES2874452T3 (pt) |
IN (1) | IN2014CN00675A (pt) |
MX (1) | MX352827B (pt) |
RU (1) | RU2719194C2 (pt) |
WO (1) | WO2013011479A2 (pt) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
EP2549399A1 (en) | 2011-07-19 | 2013-01-23 | Koninklijke Philips Electronics N.V. | Assessment of Wnt pathway activity using probabilistic modeling of target gene expression |
EP2820151B1 (en) | 2012-02-28 | 2020-03-25 | Novartis AG | Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status |
US9828603B2 (en) | 2012-08-13 | 2017-11-28 | Cedars Sinai Medical Center | Exosomes and micro-ribonucleic acids for tissue regeneration |
EP2938745B1 (en) | 2012-12-26 | 2020-10-07 | Koninklijke Philips N.V. | Assessment of cellular signaling pathway activity using linear combination(s) of target gene expressions |
TWI582239B (zh) * | 2013-03-11 | 2017-05-11 | 諾華公司 | 與wnt抑制劑相關之標記 |
BR112015026736A2 (pt) * | 2013-04-26 | 2017-07-25 | Koninklijke Philips Nv | método, aparelho, mídia de armazenamento não transitório, programa de computador, e, sinal |
KR20160084363A (ko) | 2013-06-28 | 2016-07-13 | 난토믹스, 엘엘씨 | 진단 검사의 확인을 위한 경로 분석 |
JP2017502983A (ja) | 2013-10-02 | 2017-01-26 | スリ テクノロジーズ エルティーディー. | 不均一な腫瘍を処置するための患者特異的免疫療法 |
US11261495B2 (en) | 2014-01-03 | 2022-03-01 | Koninklijke Philips N.V. | Assessment of the PI3K cellular signaling pathway activity using mathematical modelling of target gene expression |
US9880257B2 (en) * | 2014-09-11 | 2018-01-30 | Google Llc | Gaussian process-based approach for identifying correlation between wireless signals |
US9838847B2 (en) | 2014-09-11 | 2017-12-05 | Google LLP | Data driven evaluation and rejection of trained Gaussian process-based wireless mean and standard deviation models |
US9810762B2 (en) * | 2014-09-11 | 2017-11-07 | Google Inc. | Calculating mean wireless signal strengths using a gaussian process approach incorporating predictive standard deviations |
CA2961725C (en) | 2014-09-19 | 2023-04-04 | The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy And Undiv. Trinity Of Queen Elizabeth, Near Dublin | A method of predicting risk of recurrence of cancer |
US11357799B2 (en) | 2014-10-03 | 2022-06-14 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
CN108064380A (zh) * | 2014-10-24 | 2018-05-22 | 皇家飞利浦有限公司 | 使用多种细胞信号传导途径活性的医学预后和治疗反应的预测 |
JP7065609B6 (ja) * | 2014-10-24 | 2022-06-06 | コーニンクレッカ フィリップス エヌ ヴェ | 複数の細胞シグナル伝達経路活性を用いる治療応答の医学的予後及び予測 |
CN107077536B (zh) * | 2014-10-24 | 2021-09-28 | 皇家飞利浦有限公司 | 使用靶基因表达的数学建模评价TGF-β细胞信号传导途径的活性 |
CN105760707B (zh) * | 2014-12-18 | 2018-07-31 | 中国科学院大连化学物理研究所 | 细胞基因翻译过程建模方法 |
US11450409B2 (en) | 2015-08-14 | 2022-09-20 | Innosign B.V. | Determination of NFkB pathway activity using unique combination of target genes |
WO2017033154A1 (en) * | 2015-08-27 | 2017-03-02 | Koninklijke Philips N.V. | An integrated method and system for identifying functional patient-specific somatic aberations using multi-omic cancer profiles |
CN106897578B (zh) * | 2015-12-15 | 2020-02-14 | 中国科学院大连化学物理研究所 | 一种细胞基因翻译过程建模方法 |
US11253551B2 (en) | 2016-01-11 | 2022-02-22 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
US20170329914A1 (en) * | 2016-05-11 | 2017-11-16 | International Business Machines Corporation | Predicting Personalized Cancer Metastasis Routes, Biological Mediators of Metastasis and Metastasis Blocking Therapies |
US11351200B2 (en) | 2016-06-03 | 2022-06-07 | Cedars-Sinai Medical Center | CDC-derived exosomes for treatment of ventricular tachyarrythmias |
US10621236B2 (en) * | 2016-09-16 | 2020-04-14 | At&T Intellectual Property I, L.P. | Concept based querying of graph databases |
EP3515459A4 (en) | 2016-09-20 | 2020-08-05 | Cedars-Sinai Medical Center | CELLS DERIVED FROM CARDIOSPHERES AND THEIR EXTRACELLULAR VESICLES TO DELAY OR REVERSE AGING AND AGE-RELATED DISORDERS |
EP3538673A4 (en) | 2016-11-11 | 2019-12-04 | University of Pittsburgh- Of the Commonwealth System of Higher Education | IDENTIFICATION OF SOMATIC ALTERATIONS OF GENOME SPECIFIC TO AN INSTANCE HAVING A FUNCTIONAL IMPACT |
BR112019010553A2 (pt) | 2016-11-25 | 2019-09-10 | Koninklijke Philips Nv | método para inferir a atividade de uma via de sinalização celular pi3k em um indivíduo e programa de computador |
CN106755464A (zh) * | 2017-01-11 | 2017-05-31 | 上海易毕恩基因科技有限公司 | 用于筛选肠癌和/或胃癌的基因标志物的方法、用该方法筛选的基因标志物及其用途 |
CN108300783A (zh) * | 2017-01-11 | 2018-07-20 | 上海易毕恩基因科技有限公司 | 用于筛选肠癌和/或胃癌的基因标志物的方法、用该方法筛选的基因标志物及其用途 |
WO2018195210A1 (en) | 2017-04-19 | 2018-10-25 | Cedars-Sinai Medical Center | Methods and compositions for treating skeletal muscular dystrophy |
CN107184991B (zh) * | 2017-05-03 | 2020-05-26 | 武汉爱博泰克生物科技有限公司 | PRDM15基因序列在制备NF-κB抑制剂中的应用 |
CN107164508A (zh) * | 2017-06-16 | 2017-09-15 | 上海易毕恩基因科技有限公司 | 用于检测肝癌的基因标志物及其用途 |
EP3431582A1 (en) | 2017-07-18 | 2019-01-23 | Koninklijke Philips N.V. | Cell culturing materials |
CN107201411A (zh) * | 2017-07-27 | 2017-09-26 | 上海市长宁区妇幼保健院 | Mylk基因作为诊断子宫内膜癌的标志物 |
CN107385051A (zh) * | 2017-08-04 | 2017-11-24 | 上海易毕恩生物技术有限公司 | 用于检测肝肿瘤良恶性的基因标志物、试剂盒及检测方法 |
EP3462348A1 (en) * | 2017-09-28 | 2019-04-03 | Koninklijke Philips N.V. | Bayesian inference |
EP3692170A1 (en) | 2017-10-02 | 2020-08-12 | Koninklijke Philips N.V. | Determining functional status of immune cells types and immune response |
EP3461915A1 (en) * | 2017-10-02 | 2019-04-03 | Koninklijke Philips N.V. | Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression |
EP3461916A1 (en) | 2017-10-02 | 2019-04-03 | Koninklijke Philips N.V. | Assessment of jak-stat3 cellular signaling pathway activity using mathematical modelling of target gene expression |
EP3462349A1 (en) * | 2017-10-02 | 2019-04-03 | Koninklijke Philips N.V. | Assessment of notch cellular signaling pathway activity using mathematical modelling of target gene expression |
EP3502279A1 (en) | 2017-12-20 | 2019-06-26 | Koninklijke Philips N.V. | Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression |
US11660355B2 (en) | 2017-12-20 | 2023-05-30 | Cedars-Sinai Medical Center | Engineered extracellular vesicles for enhanced tissue delivery |
US11475995B2 (en) * | 2018-05-07 | 2022-10-18 | Perthera, Inc. | Integration of multi-omic data into a single scoring model for input into a treatment recommendation ranking |
CN108875009B (zh) * | 2018-06-16 | 2021-10-22 | 上海豹云网络信息服务有限公司 | 一种用于对数据文件进行动态处理的方法及系统 |
US11354591B2 (en) | 2018-10-11 | 2022-06-07 | International Business Machines Corporation | Identifying gene signatures and corresponding biological pathways based on an automatically curated genomic database |
US20220076785A1 (en) * | 2018-12-21 | 2022-03-10 | Phil Rivers Technology, Ltd. | Method for acquiring intracellular deterministic event, electronic device and storage medium |
US11674185B2 (en) | 2019-05-03 | 2023-06-13 | Koninklijke Philips N.V. | Methods of prognosis in high-grade serous ovarian cancer |
EP3812474A1 (en) | 2019-10-22 | 2021-04-28 | Koninklijke Philips N.V. | Methods of prognosis in high-grade serous ovarian cancer |
EP3965800A4 (en) * | 2019-05-08 | 2023-02-15 | Cedars-Sinai Medical Center | THERAPEUTIC ACTIVE CELLS AND EXOSOMES |
EP3739588A1 (en) | 2019-05-13 | 2020-11-18 | Koninklijke Philips N.V. | Assessment of multiple signaling pathway activity score in airway epithelial cells to predict airway epithelial abnormality and airway cancer risk |
WO2021034712A1 (en) * | 2019-08-16 | 2021-02-25 | Tempus Labs, Inc. | Systems and methods for detecting cellular pathway dysregulation in cancer specimens |
EP3822368A1 (en) | 2019-11-14 | 2021-05-19 | Koninklijke Philips N.V. | Assessment of pr cellular signaling pathway activity using mathematical modelling of target gene expression |
EP3835433A1 (en) | 2019-12-12 | 2021-06-16 | Koninklijke Philips N.V. | Notch signaling pathway activity as prognostic marker in bladder cancer |
EP4073807A4 (en) * | 2019-12-12 | 2024-05-01 | Tempus AI, Inc. | REAL-WORLD EVIDENCE ON DIAGNOSTIC TESTING AND TREATMENT PATTERNS IN BREAST CANCER PATIENTS IN THE USA |
CN111139300B (zh) * | 2020-02-19 | 2021-08-17 | 伯克利南京医学研究有限责任公司 | 一组结肠癌预后相关基因的应用 |
EP3882363A1 (en) | 2020-03-17 | 2021-09-22 | Koninklijke Philips N.V. | Prognostic pathways for high risk sepsis patients |
EP3978628A1 (en) | 2020-10-01 | 2022-04-06 | Koninklijke Philips N.V. | Prognostic pathways for viral infections |
US20230223108A1 (en) | 2020-04-16 | 2023-07-13 | Innosign B.V. | Prognostic pathways for viral infections |
CN111739586B (zh) * | 2020-06-17 | 2024-04-05 | 浙江大学 | 以87个基因作为生物标志物预测细胞增殖活性的模型 |
EP3940704A1 (en) | 2020-07-14 | 2022-01-19 | Koninklijke Philips N.V. | Method for determining the differentiation state of a stem cell |
EP3960875A1 (en) | 2020-08-28 | 2022-03-02 | Koninklijke Philips N.V. | Pcr method and kit for determining pathway activity |
EP3965119A1 (en) | 2020-09-04 | 2022-03-09 | Koninklijke Philips N.V. | Methods for estimating heterogeneity of a tumour based on values for two or more genome mutation and/or gene expression related parameter, as well as corresponding devices |
EP3974540A1 (en) | 2020-09-25 | 2022-03-30 | Koninklijke Philips N.V. | Method for predicting immunotherapy resistance |
EP4015651A1 (en) | 2020-12-17 | 2022-06-22 | Koninklijke Philips N.V. | Treatment prediction and effectiveness of anti-tnf alpha treatment in ibd patients |
EP4039825A1 (en) | 2021-02-09 | 2022-08-10 | Koninklijke Philips N.V. | Comparison and standardization of cell and tissue culture |
JP2024514404A (ja) | 2021-03-11 | 2024-04-02 | コーニンクレッカ フィリップス エヌ ヴェ | 高リスク敗血症患者のための予後経路 |
CN113278700B (zh) * | 2021-06-04 | 2022-08-09 | 浙江省肿瘤医院 | 一种用于乳腺癌分型及预后预测的引物组及试剂盒 |
EP4434034A1 (en) | 2021-11-15 | 2024-09-25 | InnoSIGN B.V. | Assessment of gr cellular signaling pathway activity using mathematical modelling of target gene expression |
CN113963745A (zh) * | 2021-12-07 | 2022-01-21 | 国际竹藤中心 | 一种构建植物发育分子调控网络的方法及其应用 |
WO2024033063A1 (en) | 2022-08-12 | 2024-02-15 | Innosign B.V. | Prediction and monitoring of immunotherapy in cancer |
CN116083590B (zh) * | 2023-03-23 | 2024-03-22 | 雄安妙心医学检验有限公司 | 一种基因检测试剂盒及其制备方法和应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6566130B1 (en) * | 2000-01-28 | 2003-05-20 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Androgen-regulated gene expressed in prostate tissue |
US7371736B2 (en) * | 2001-11-07 | 2008-05-13 | The Board Of Trustees Of The University Of Arkansas | Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss |
EP1380644A1 (en) | 2002-07-08 | 2004-01-14 | Kylix B.V. | The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role |
WO2004022575A2 (en) | 2002-09-05 | 2004-03-18 | Toolgen, Inc. | Bioinformatics analysis of cellular effects of artificial transcription factors |
US20070009923A1 (en) * | 2005-01-24 | 2007-01-11 | Massachusetts Institute Of Technology | Use of bayesian networks for modeling cell signaling systems |
CA2608359A1 (en) * | 2005-05-13 | 2006-11-23 | Duke University | Gene expression signatures for oncogenic pathway deregulation |
US20070112567A1 (en) | 2005-11-07 | 2007-05-17 | Scanscout, Inc. | Techiques for model optimization for statistical pattern recognition |
WO2007136787A2 (en) | 2006-05-17 | 2007-11-29 | The Trustees Of Boston University | Method to determine transcriptional regulation pathways in organisms |
WO2008086182A2 (en) * | 2007-01-04 | 2008-07-17 | University Of Rochester | Use of gene signatures to design novel cancer treatment regimens |
JP2010178650A (ja) | 2009-02-04 | 2010-08-19 | Univ Of Tokyo | 固形癌の再発予測のための試験方法および再発予防剤 |
EP2694963B1 (en) | 2011-04-01 | 2017-08-02 | Qiagen | Gene expression signature for wnt/b-catenin signaling pathway and use thereof |
EP2705164A1 (en) * | 2011-05-05 | 2014-03-12 | Clinical Genomics Pty Ltd | A method of diagnosing neoplasms |
EP2549399A1 (en) | 2011-07-19 | 2013-01-23 | Koninklijke Philips Electronics N.V. | Assessment of Wnt pathway activity using probabilistic modeling of target gene expression |
-
2011
- 2011-08-19 EP EP11178148A patent/EP2549399A1/en not_active Ceased
-
2012
- 2012-07-19 ES ES18180343T patent/ES2874452T3/es active Active
- 2012-07-19 EP EP22177533.1A patent/EP4130291B1/en active Active
- 2012-07-19 EP EP18180343.8A patent/EP3418396B1/en active Active
- 2012-07-19 WO PCT/IB2012/053686 patent/WO2013011479A2/en active Application Filing
- 2012-07-19 KR KR1020147003879A patent/KR102064004B1/ko active IP Right Grant
- 2012-07-19 ES ES12751371.1T patent/ES2617195T3/es active Active
- 2012-07-19 CN CN201811176740.5A patent/CN109852671A/zh active Pending
- 2012-07-19 DK DK12751371.1T patent/DK2734643T3/en active
- 2012-07-19 EP EP12751371.1A patent/EP2734643B1/en active Active
- 2012-07-19 US US14/233,546 patent/US11443831B2/en active Active
- 2012-07-19 EP EP20209212.8A patent/EP3831957B1/en active Active
- 2012-07-19 DK DK18180343.8T patent/DK3418396T3/da active
- 2012-07-19 IN IN675CHN2014 patent/IN2014CN00675A/en unknown
- 2012-07-19 RU RU2014106026A patent/RU2719194C2/ru active
- 2012-07-19 MX MX2014000557A patent/MX352827B/es active IP Right Grant
- 2012-07-19 CN CN201280035666.XA patent/CN103649337B/zh active Active
- 2012-07-19 ES ES16192584T patent/ES2700617T3/es active Active
- 2012-07-19 BR BR112014000965A patent/BR112014000965B8/pt active IP Right Grant
- 2012-07-19 JP JP2014520772A patent/JP6204354B2/ja not_active Expired - Fee Related
- 2012-07-19 EP EP16192584.7A patent/EP3173489B1/en active Active
- 2012-07-19 DK DK16192584.7T patent/DK3173489T3/en active
-
2017
- 2017-08-31 JP JP2017167175A patent/JP6783729B2/ja not_active Expired - Fee Related
-
2019
- 2019-05-07 JP JP2019087335A patent/JP6807430B2/ja not_active Expired - Fee Related
-
2022
- 2022-08-24 US US17/821,839 patent/US20230105263A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014000965B8 (pt) | Método, aparelho e meio de armazenamento não transitório | |
BR112015015131A2 (pt) | método, aparelho, mídia de armazenamento não transitório, programa de computador, e produto | |
BR112017007965A2 (pt) | método implantado por computador para inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; aparelho para inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; meio de armazenamento não transitório; programa de computador; kits para medir níveis de expressão de três ou mais genes-alvo da via de sinalização celular de tgf-b em uma amostra de um indivíduo; inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; e uso do kit | |
BR112016003868A2 (pt) | método, aparelho, mídia de armazenamento não transitório, e, programa de computador | |
BR112018002848A2 (pt) | método, aparelho, mídia de armazenamento não transitório, programa de computador, kit para medir níveis de expressão de seis ou mais genes-alvo da via de sinalização celular | |
BR112018069849A2 (pt) | kit, dispositivo e método para a detecção de câncer pancreático precoce ou de lesão precursora do câncer pancreático | |
SA517390218B1 (ar) | جهاز وطرق لتحديد النسيج التالف باستخدام قياسات الرطوبة تحت الجلد | |
EA201891292A1 (ru) | Мультиспецифические антитела | |
BR112018010933A2 (pt) | anticorpos multiespecíficos | |
NZ621733A (en) | Lung cancer biomarkers and uses thereof | |
BR112015018213A2 (pt) | método para determinar a síndrome da angústia respiratória aguda (ards) relacionada aos biomarcadores, um método para monitorar o desenvolvimento e o tratamento da ards em um paciente | |
MY187050A (en) | Cancer cell-specific antibody, anticancer agent, and cancer testing method | |
MX2015014892A (es) | Metodo para un ensayo de deteccion de farmacos basado en celulas y el uso del mismo. | |
BR102012002812A8 (pt) | método para determinar a influência de uma variável em um fenômeno | |
MX2017012732A (es) | Sistema para analisis automatizado de valores de laboratorio y notificacion de riesgo en unidad de cuidados intensivos. | |
EA201691682A1 (ru) | Способы анализирования редких циркулирующих в крови клеток | |
BR112017003167A2 (pt) | método in vitro e aparelho para análise do comportamento de substâncias em ambiente fisiológico simulado | |
MX2022003399A (es) | Metodo basado en celulas para determinar la potencia de la defibrotida. | |
BR112016002709A2 (pt) | queratinas como biomarcadores para câncer cervical e sobrevivência | |
WO2014198670A3 (en) | Methods of viewing and analyzing high content biological data | |
CO7151536A2 (es) | Bioensayos con calidad controlada basados en células para productos nutricéuticos y medicinales | |
MX357018B (es) | Método de diagnóstico temprano de carcinoma hepatocelular. | |
AR101088A1 (es) | Caracterización biológica de un producto farmacológico derivado de acetato de glatiramer mediante células de mamífero humano y no humano | |
TW201613622A (en) | Composition for skincare and pharmaceutical composition and preparation method thereof | |
Karta et al. | An assessment of antioxidant status in patients with carbon monoxide poisoning |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/07/2012, OBSERVADAS AS CONDICOES LEGAIS. |
|
B25A | Requested transfer of rights approved |
Owner name: INNOSIGN B.V. (NL) |